This was confirmed by in vitro studies where the PKC inhibitor GF109203X significantly inhibited WNT5A induced cell migration, invasion, and clonogenicity in A549 and A549/DDP (diamminedichloroplatinum) lung cancer cells, indicating a clear WNT5A role in promoting lung cancer cell mobility through WNT/PKC noncanonical pathway activation [97]. The gene discussed is WNT5A; the disease is lung carcinoma.